Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke

Clinical Neurology and Neurosurgery

Volumn 113, Issue 5, 2011, Pages 380-386

  Meng, Ran ^a,f   Li, Zhi Yong ^c,d   Ji, Xunming ^b   Ding, Yuchuan ^b   Meng, Sui ^e   Wang, Xiaoying ^f  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF INTERNATIONAL BUSINESS AND ECONOMICS   (China)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute; Antithrombin III; Fibrinogen; Ischemic stroke

Indexed keywords

ANTITHROMBIN III; BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBRAL ISCHEMIC STROKE; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; LIMB WEAKNESS; MAJOR CLINICAL STUDY; MALE; PARESTHESIA; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VERTIGO;

ADULT; AGED; ANTITHROMBIN III; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; COSTS AND COST ANALYSIS; DIABETES MELLITUS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79955877411     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.12.016     Document Type: Article

References (35)

1. Persky RW, Turtzo LC, McCullough LD. Stroke in women: disparities and outcomes. Curr Cardiol Rep 2010;12(1):6-13.
2. Flynn RW, MacWalter RS, Doney AS. The cost of cerebral ischaemia. Neuropharmacology 2008;55(3):250-6.
3. Al-Buhairi AR, Jan MM. Recombinant tissue plasminogen activator for acute ischemic stroke. Saudi Med J 2002;23(1):13-9. (Pubitemid 34187713)
4. Stemer A, Lyden P. Evolution of the thrombolytic treatment window for acute ischemic stroke. Curr Neurol Neurosci Rep 2010;10(1):29-33.
5. Selvaratnam R, Srirangalingam U, Ahmad S. Thrombolysis beyond 3 hours for acute ischaemic stroke. Emerg Med J 2009;26(10):756-7.
6. Saver JL, Gornbein J, Grotta J. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5- hour window: joint outcome table analysis of the ECASS 3 trial. Stroke 2009;40(7):2433-7.
7. Demaerschalk BM, Bobrow BJ, Paulsen M. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience. Stroke 2008;39(4):1246-53. (Pubitemid 351440698)
8. Amarenco P, Labreuche J, Lavallée PC. Does ABCD2 score below 4 allow more time to evaluate patients with a transient ischemic attack? Stroke 2009;40(9):3091-5.
9. Hatzitolios A, Savopoulos C, Ntaios G. Stroke and conditions that mimic it: a protocol secures a safe early recognition. Hippokratia 2008;12(2):98-102. (Pubitemid 351468524)
10. Wardlaw JM, Farrall AJ, Perry D. Factors influencing the detection of early CT signs of cerebral ischemia: an internet-based, international multiobserver study. Stroke 2007;38(4):1250-6. (Pubitemid 351664270)
11. Srivastava AK, Mehrotra G, Bhargava SK. Studies on the time course of apparent diffusion coefficient and signal intensities on T2- and diffusion-weighted MR Imaging in acute cerebral ischemic stroke. J Med Phys 2008;33(4):162-70.
12. Ma H, Zavala JA, Teoh H. Fragmentation of the classical magnetic resonance mismatch "penumbral" pattern with time. Stroke 2009;40(December (12)):3752-7.
13. Meng R, Ji X, Li B. Dynamical levels of plasma F(1+2) and D-dimer in patients with acute cerebral infarction during intravenous urokinase thrombolysis. Neurol Res 2009;31(4):367-70.
14. Stehling F, Weber R, Ozcelik A. Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy. Neurosci Lett 2008;441(1):39-43.
15. Meyer dos Santos S, Klinkhardt U, Schneppenheim R. Using Image J for the quantitative analysis of flow-based adhesion assays in real-time under physiologic flow conditions. Platelets 2010;21(1):60-6.
16. Seitz RJ, Siebler M. Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease. Curr Vasc Pharmacol 2008;6(1):29-36.
17. Huang PH, Chen JW, Lu TM. Combined use of endothelial function assessed by brachial ultrasound and high-sensitive C-reactive protein in predicting cardiovascular events. Clin Cardiol 2007;30(3):135-40.
18. Sheehan OC, Merwick A, Kelly LA. Diagnostic usefulness of the ABCD2 score to distinguish transient ischemic attack and minor ischemic stroke from noncerebrovascular events: the North Dublin TIA Study. Stroke 2009;40(11):3449-54.
19. Coutts SB, Eliasziw M, Hill MD. An improved scoring system for identifying patients at high early risk of stroke and functional impairment after an acute transient ischemic attack or minor stroke. Int J Stroke 2008;3: 3-10. (Pubitemid 351228139)
20. Girtovitis FI, Ntaios G, Papadopoulos A. Defective platelet aggregation in myelodysplastic syndromes. Acta Haematol 2007;118(2):117-22. (Pubitemid 47413796)
21. Rana R, Singh A. Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance. J Assoc Physicians India 2010;58:77-83.
22. James PR, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9:228S-33S.
23. Hayashi S. Significance of plasma D-dimer in relation to the severity of atherosclerosis among patients evaluated by non-invasive indices of cardioankle vascular index and carotid intima-media thickness. Int J Hematol 2010;92(1):76-82.
24. Di Napoli M, Singh P. Is plasma fibrinogen useful in evaluating ischemic stroke patients? Why, how, and when. Stroke 2009;40(5):1549-52.
25. del Zoppo GJ, Levy DE, Wasiewski WW. Hyperfibrinogenemia and functional outcome from acute ischemic stroke. Stroke 2009;40(5):1687-91.
26. Tanne D, Macko RF, Lin Y. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 2006;37(7):1798-804. (Pubitemid 44297732)
27. Kataoka S, Hirose G, Hori A. Activation of thrombosis and fibrinolysis following brain infarction. J Neurol Sci 2000;181(1-2):82-8.
28. D'Uva M, Di Micco P, Strina I. Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy. Biologics 2008;2(4):897-902.
29. Ntaios G, Gurer O, Faouzi M. Mean platelet volume in the early phase of acute ischemic stroke is not associated with severity or functional outcome. Cerebrovasc Dis 2010;29(5):484-9.
30. Guimarães AH, de Bruijne EL, Lisman T. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009;145(1):115-20.
31. Chuang SY, Bai CH, Chen WH. Fibrinogen independently predicts the development of ischemic stroke in a Taiwanese population: CVDFACTS study. Stroke 2009;40(5):1578-84.
32. Isenegger J, Meier N, Lämmle B. D-dimers predict stroke sub type when assessed early. Cerebrovasc Dis 2009;29(1):82-6.
33. Sienkiewicz-Jarosz H, Galecka-Wolska M, Bidziński A. Predictive value of selected biochemical markers of brain damage for functional outcome in ischaemic stroke patients. Neurol Neurochir Pol 2009;43(2):126-33.
34. Nakase T, Yamazaki T, Ogura N. The impact of inflammation on the pathogenesis and prognosis of ischemic stroke. J Neurol Sci 2008;271(1-2):104-9.
35. Sander K, Horn CS, Briesenick C. High-sensitivity C-reactive protein is independently associated with early carotid artery progression in women but not in men: the INVADE study. Stroke 2007;38(11):2881-6.